Thus, it is suggested that inhibition of hepatic IKK-β/IκB/NF-κB-mediated chronic inflammation and attenuation of fatty liver are responsible for rosiglitazone-elicited improvement of hepatic insulin resistance in OLETF rats. This evidence concerns the gene IKBKB and fatty liver disease.